DK1370553T3 - Rho-kinase-inhibitorer - Google Patents
Rho-kinase-inhibitorerInfo
- Publication number
- DK1370553T3 DK1370553T3 DK02719303T DK02719303T DK1370553T3 DK 1370553 T3 DK1370553 T3 DK 1370553T3 DK 02719303 T DK02719303 T DK 02719303T DK 02719303 T DK02719303 T DK 02719303T DK 1370553 T3 DK1370553 T3 DK 1370553T3
- Authority
- DK
- Denmark
- Prior art keywords
- kinase inhibitors
- rho kinase
- rho
- inhibitors
- kinase
- Prior art date
Links
- 239000003590 rho kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27797401P | 2001-03-23 | 2001-03-23 | |
| US31534101P | 2001-08-29 | 2001-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1370553T3 true DK1370553T3 (da) | 2006-09-11 |
Family
ID=26958819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02719303T DK1370553T3 (da) | 2001-03-23 | 2002-03-22 | Rho-kinase-inhibitorer |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20030125344A1 (es) |
| EP (1) | EP1370553B1 (es) |
| JP (1) | JP4329003B2 (es) |
| AR (1) | AR035791A1 (es) |
| AT (1) | ATE325795T1 (es) |
| AU (1) | AU2002250394A1 (es) |
| CA (1) | CA2441492C (es) |
| CY (1) | CY1107475T1 (es) |
| DE (1) | DE60211317T2 (es) |
| DK (1) | DK1370553T3 (es) |
| ES (1) | ES2264477T3 (es) |
| HN (1) | HN2002000067A (es) |
| MX (1) | MXPA03008658A (es) |
| MY (1) | MY134783A (es) |
| PE (1) | PE20021011A1 (es) |
| PT (1) | PT1370553E (es) |
| TW (1) | TWI261055B (es) |
| UY (1) | UY27224A1 (es) |
| WO (1) | WO2002076976A2 (es) |
Families Citing this family (167)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03008658A (es) * | 2001-03-23 | 2005-04-11 | Bayer Ag | Inhibidores de rho-cinasa. |
| UY27225A1 (es) * | 2001-03-23 | 2002-10-31 | Bayer Corp | Inhibidores de la rho-quinasa |
| WO2002100833A1 (en) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Rho KINASE INHIBITORS |
| CA2472619A1 (en) * | 2002-01-10 | 2003-07-24 | Bayer Corporation | Fused pyrimidine derivates as rho-kinase inhibitors |
| US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| ES2382733T3 (es) | 2002-08-29 | 2012-06-13 | Santen Pharmaceutical Co., Ltd. | Remedio para el glaucoma que comprende un inhibidor de la Rho quinasa y prostaglandinas |
| EP1608631A4 (en) | 2003-03-28 | 2008-08-20 | Scios Inc | BICYCLIC PYRIMIDININHIBITORS OF TGF BETA |
| GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
| CA2520323C (en) * | 2003-04-09 | 2013-07-09 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| US20040266755A1 (en) * | 2003-05-29 | 2004-12-30 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine |
| US20080146562A1 (en) * | 2003-08-08 | 2008-06-19 | Ulysses Pharmaceutical Products Inc., | Halogenated quinazolinyl nitrofurans as antibacterial agents |
| CA2534405A1 (en) * | 2003-08-08 | 2005-02-17 | Ulysses Pharmaceutical Products Inc. | Halogenated quinazolinyl nitrofurans as antibacterial agents |
| US7569577B2 (en) | 2003-09-16 | 2009-08-04 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| EP1689393A4 (en) * | 2003-10-06 | 2008-12-17 | Glaxo Group Ltd | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS |
| EP1670466A4 (en) * | 2003-10-06 | 2007-04-25 | Glaxo Group Ltd | PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS |
| ES2387780T3 (es) * | 2003-10-06 | 2012-10-01 | Glaxosmithkline Llc | Preparación de azabencimidazoles 1,6-disustituidos como inhibidores de quinasas |
| WO2005035506A1 (ja) | 2003-10-15 | 2005-04-21 | Ube Industries, Ltd. | 新規インダゾール誘導体 |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
| CN1933839A (zh) | 2004-01-23 | 2007-03-21 | 安进公司 | 化合物和使用方法 |
| JP2007518823A (ja) | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途 |
| ATE413389T1 (de) | 2004-02-03 | 2008-11-15 | Astrazeneca Ab | Chinazolinderivate |
| DE102004017438A1 (de) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
| KR101258298B1 (ko) * | 2004-06-01 | 2013-04-25 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 암 및 혈관형성의 이중 소분자 억제제 |
| WO2005120509A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| JP2007269629A (ja) * | 2004-06-21 | 2007-10-18 | Astellas Pharma Inc | キナゾリン誘導体 |
| BRPI0516751A (pt) | 2004-09-30 | 2008-09-16 | Tibotec Pharm Ltd | pirimidinas bicìclicas que inibem hcv |
| JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| EP1833832A1 (en) * | 2004-12-31 | 2007-09-19 | GPC Biotech AG | Napthyridine compounds as rock inhibitors |
| JP2006219395A (ja) * | 2005-02-09 | 2006-08-24 | Koei Chem Co Ltd | ビピリジン化合物の製造方法 |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| JP4966958B2 (ja) * | 2005-03-14 | 2012-07-04 | ノイロサーチ アクティーゼルスカブ | カリウムチャネル調節剤及び医療における使用 |
| WO2006100310A1 (en) | 2005-03-25 | 2006-09-28 | Tibotec Pharmaceuticals Ltd | Heterobicylic inhibitors of hcv |
| CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| AR056347A1 (es) | 2005-05-12 | 2007-10-03 | Tibotec Pharm Ltd | Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| ES2331853T3 (es) | 2005-06-28 | 2010-01-18 | Sanofi-Aventis | Derivados de isoquinolina como inhibidores de rho-cinasa. |
| EP1932841B1 (en) | 2005-08-30 | 2014-01-01 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| US8211919B2 (en) | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| EP2001480A4 (en) * | 2006-03-31 | 2011-06-15 | Abbott Lab | Indazole CONNECTIONS |
| CA2653424A1 (en) | 2006-06-08 | 2007-12-13 | Ube Industries, Ltd. | Novel indazole derivative having spiro ring structure in side chain |
| WO2007146230A2 (en) * | 2006-06-14 | 2007-12-21 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| RS53588B1 (sr) | 2006-12-08 | 2015-02-27 | Irm Llc | Jedinjenja i kompozicije kao inhibitori protein kinaza |
| BRPI0720264B1 (pt) * | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
| WO2008079945A2 (en) * | 2006-12-20 | 2008-07-03 | University Of South Florida | Rock inhibitors and uses thereof |
| EA200901041A1 (ru) | 2007-02-06 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения |
| US8415372B2 (en) | 2007-02-27 | 2013-04-09 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| CN101622243B (zh) | 2007-02-28 | 2013-12-04 | 旭化成制药株式会社 | 磺酰胺衍生物 |
| AU2008272396B2 (en) | 2007-07-02 | 2011-09-08 | Asahi Kasei Pharma Corporation | Sulfonamide Compound and Crystal Thereof |
| KR20100080514A (ko) | 2007-08-29 | 2010-07-08 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
| RS52573B (sr) | 2008-02-07 | 2013-04-30 | Boehringer Ingelheim International Gmbh | Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju |
| BRPI0912170A2 (pt) | 2008-05-13 | 2015-10-13 | Astrazeneca Ab | composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente |
| CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| CN101463014B (zh) * | 2008-12-26 | 2013-07-10 | 复旦大学 | 二芳基苯并嘧啶类衍生物及其药物组合物和用途 |
| JP2012519732A (ja) * | 2009-03-09 | 2012-08-30 | サーフェイス ロジックス，インコーポレイティド | Ｒｈｏキナーゼ阻害剤 |
| WO2010124142A2 (en) | 2009-04-22 | 2010-10-28 | Cythera, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| ES2638464T3 (es) | 2009-10-16 | 2017-10-20 | The Scripps Research Institute | Inducción de células pluripotentes |
| CA2777552C (en) | 2009-10-19 | 2019-05-21 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
| US9126978B2 (en) | 2009-11-17 | 2015-09-08 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| WO2011092695A1 (en) | 2010-01-28 | 2011-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Quinazoline-based t cell proliferation inhibitors |
| ES2552977T3 (es) * | 2010-05-07 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolinas como inhibidores de quinasa |
| US8691574B2 (en) | 2010-06-15 | 2014-04-08 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| WO2012046132A1 (en) | 2010-10-05 | 2012-04-12 | Purdue Pharma L.P. | Quinazoline compounds as sodium channel blockers |
| CN106893692B (zh) | 2010-12-22 | 2021-11-26 | 菲特治疗公司 | 用于单细胞分选与增强ipsc重新编程的细胞培养平台 |
| CN103857288B (zh) | 2011-03-04 | 2016-09-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为激酶抑制剂的氨基-喹啉 |
| US9487752B2 (en) | 2011-03-30 | 2016-11-08 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| JP2014520551A (ja) | 2011-07-11 | 2014-08-25 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 細胞のリプログラミング方法およびゲノムの改変方法 |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| CA2858173C (en) | 2011-12-06 | 2023-09-26 | Advanced Cell Technology, Inc. | Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof |
| WO2013100208A1 (ja) | 2011-12-28 | 2013-07-04 | 京都府公立大学法人 | 角膜内皮細胞の培養正常化 |
| EP2628482A1 (en) | 2012-02-17 | 2013-08-21 | Academisch Medisch Centrum | Rho kinase inhiitors for use in the treatment of neuroblastoma |
| EP2826855B1 (en) | 2012-03-15 | 2018-08-29 | iHeart Japan Corporation | Myocardial sheet |
| US9334475B2 (en) | 2012-04-06 | 2016-05-10 | Kyoto University | Method for inducing erythropoietin-producing cell |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
| EP2958895B1 (en) | 2013-02-20 | 2020-08-19 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| EP2958911B1 (en) | 2013-02-21 | 2017-10-18 | GlaxoSmithKline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
| US10266807B2 (en) | 2013-04-03 | 2019-04-23 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
| JP6461787B2 (ja) | 2013-04-12 | 2019-01-30 | 国立大学法人京都大学 | 肺胞上皮前駆細胞の誘導方法 |
| EP3020803B1 (en) | 2013-06-11 | 2020-03-11 | Kyoto University | Method for producing renal precursor cells |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| ES2661437T3 (es) * | 2013-06-21 | 2018-04-02 | Zenith Epigenetics Corp. | Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio |
| EP3029140A4 (en) | 2013-07-30 | 2017-06-28 | Kyoto Prefectural Public University Corporation | Corneal endothelial cell marker |
| CN105593224B (zh) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
| US9796962B2 (en) | 2013-08-07 | 2017-10-24 | Kyoto University | Method for generating pancreatic hormone-producing cells |
| SG11201601720RA (en) | 2013-09-05 | 2016-04-28 | Univ Kyoto | New method for inducing dopamine-producing neural precursor cells |
| EP3055301B1 (en) | 2013-10-07 | 2019-11-20 | Kadmon Corporation, LLC | (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amine derivatives as rho kinase inhibitors for treating autoimmune diseases |
| JPWO2015064768A1 (ja) | 2013-10-31 | 2017-03-09 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
| CA2928658A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| RU2704984C1 (ru) | 2013-11-27 | 2019-11-01 | Киото Прифекчурал Паблик Юниверсити Корпорэйшн | Применение ламинина в культуре клеток эндотелия роговицы |
| WO2015112739A1 (en) * | 2014-01-22 | 2015-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and method for treating parp1-deficient cancers |
| SG10201807292YA (en) | 2014-03-04 | 2018-09-27 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| ES2939807T3 (es) | 2014-03-21 | 2023-04-27 | Fujifilm Cellular Dynamics Inc | Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización |
| WO2015178431A1 (ja) | 2014-05-21 | 2015-11-26 | 国立大学法人京都大学 | 膵芽細胞の製造方法および膵芽細胞を含む膵疾患治療剤 |
| KR20170020527A (ko) | 2014-06-27 | 2017-02-22 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 배양된 포유동물 윤부 줄기세포, 이를 생성하는 방법, 및 이의 용도 |
| CN105367555B (zh) * | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
| WO2016104717A1 (ja) | 2014-12-26 | 2016-06-30 | 国立大学法人京都大学 | 肝細胞誘導方法 |
| US11021468B2 (en) | 2015-04-01 | 2021-06-01 | Rigel Pharmaceuticals, Inc. | TGF-ß inhibitors |
| EP4088719A1 (en) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| US12048761B2 (en) | 2015-10-13 | 2024-07-30 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| AU2016338680B2 (en) | 2015-10-16 | 2022-11-17 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
| TWI812584B (zh) | 2015-10-30 | 2023-08-21 | 美國加利福尼亞大學董事會 | 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法 |
| WO2017141926A1 (en) | 2016-02-15 | 2017-08-24 | Kyoto Prefectural Public University Corporation | Human functional corneal endothelial cell and application thereof |
| US11898163B2 (en) | 2016-04-22 | 2024-02-13 | Kyoto University | Method for producing dopaminergic neuron progenitor cell |
| WO2018035214A1 (en) | 2016-08-16 | 2018-02-22 | Cellular Dynamics International., Inc. | Methods for differentiating pluripotent cells |
| CA3036065A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN106518790B (zh) * | 2016-11-02 | 2019-01-15 | 河南省商业科学研究所有限责任公司 | 一种2,4-二氯喹唑啉的合成方法 |
| US11787783B2 (en) | 2016-12-13 | 2023-10-17 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
| BR112019012045A2 (pt) | 2016-12-13 | 2020-08-18 | Beta Therapeutics Pty Ltd | inibidores de heparanase e uso dos mesmos |
| KR102761727B1 (ko) | 2017-05-25 | 2025-02-03 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 중간 중배엽 세포로부터 신장 전구 세포로의 분화 유도 방법 및 다능성 줄기세포로부터 신장 전구 세포로의 분화 유도 방법 |
| JP7311228B2 (ja) * | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| WO2019000683A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| EP3421465B1 (en) | 2017-06-30 | 2022-10-26 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
| JP7399848B2 (ja) * | 2017-09-01 | 2023-12-18 | カドモン コーポレイション，リミティド ライアビリティ カンパニー | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 |
| RU2730864C1 (ru) | 2017-11-10 | 2020-08-26 | Редженесис Сайенс Ко., Лтд. | Способ производства культивируемых клеток и лекарственного препарата для лечения спинномозговых травм |
| JP7416700B2 (ja) | 2017-11-14 | 2024-01-17 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | 増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法 |
| CN111479568A (zh) | 2017-12-21 | 2020-07-31 | 参天制药株式会社 | 司培前列素与Rho激酶抑制剂的组合药物 |
| JP7257333B2 (ja) | 2017-12-28 | 2023-04-13 | 株式会社カネカ | 細胞凝集抑制剤 |
| CN111527197A (zh) | 2017-12-28 | 2020-08-11 | 株式会社钟化 | 细胞聚集促进剂 |
| JP7336386B2 (ja) | 2017-12-28 | 2023-08-31 | 株式会社カネカ | 多能性幹細胞凝集抑制剤 |
| EP3757208A4 (en) | 2018-02-19 | 2021-12-01 | Sumitomo Dainippon Pharma Co., Ltd. | CELL UNIT, MIXTURE OF CELL UNITS AND METHOD OF MANUFACTURING THEREOF |
| US20210332329A1 (en) | 2018-07-23 | 2021-10-28 | Kyoto University | Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same |
| WO2020047229A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| CN113056556A (zh) | 2018-08-31 | 2021-06-29 | 学校法人同志社 | 用于对眼细胞进行保存或培养的组合物以及方法 |
| CA3109705A1 (en) | 2018-10-02 | 2020-04-09 | The Doshisha | Method and vessel for preserving corneal endothelial cells |
| UY38427A (es) | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
| EP3900787A4 (en) | 2018-12-21 | 2022-02-23 | Kyoto University | LUBRICIN-LOCALIZED CARTILE-LIKE TISSUE, METHOD OF MANUFACTURE THEREOF AND COMPOSITION THEREOF FOR TREATMENT OF ARTICULATE-CARTILAGE DEFECTS |
| WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
| US20220169977A1 (en) | 2019-03-29 | 2022-06-02 | Kaneka Corporation | Cell population including pluripotent stem cells and production method thereof |
| JP7700673B2 (ja) | 2019-05-15 | 2025-07-01 | 味の素株式会社 | 神経堤細胞または角膜上皮細胞の純化方法 |
| JPWO2021172554A1 (es) | 2020-02-27 | 2021-09-02 | ||
| US20230348852A1 (en) | 2020-04-27 | 2023-11-02 | Novartis Ag | Methods and compositions for ocular cell therapy |
| JPWO2022149616A1 (es) | 2021-01-08 | 2022-07-14 | ||
| MX2023008141A (es) | 2021-01-11 | 2023-10-20 | Incyte Corp | Terapia combinada que comprende el inhibidor de la vía de proteínas tirosina cinasas de janus cinasas (jak) y el inhibidor de la proteína cinasa asociada a rho (rock). |
| US20240219375A1 (en) | 2021-04-07 | 2024-07-04 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
| JP2024519218A (ja) | 2021-05-03 | 2024-05-09 | アステラス インスティテュート フォー リジェネレイティブ メディシン | 成熟角膜内皮細胞を作製する方法 |
| WO2022259721A1 (ja) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | 間葉系幹細胞の製造方法 |
| JPWO2023017848A1 (es) | 2021-08-11 | 2023-02-16 | ||
| JP2024531682A (ja) | 2021-09-13 | 2024-08-29 | フジフィルム セルラー ダイナミクス，インコーポレイテッド | コミットされた心臓始原細胞の製造方法 |
| CA3238227A1 (en) | 2021-11-11 | 2023-05-19 | The Doshisha | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
| US20250019652A1 (en) | 2021-11-19 | 2025-01-16 | Riken | Production method for sheet-like retinal tissue |
| JPWO2023153464A1 (es) | 2022-02-09 | 2023-08-17 | ||
| CN119790139A (zh) | 2022-08-31 | 2025-04-08 | 国立大学法人京都大学 | 原始态多能干细胞的制造方法 |
| CN119948151A (zh) | 2022-09-26 | 2025-05-06 | 国立大学法人京都大学 | 胰腺内胚层细胞的制造方法 |
| WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
| WO2025224050A1 (en) | 2024-04-22 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Methods of treatment of patients suffering from hypomelanosis of ito |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US14679A (en) * | 1856-04-15 | Joel h | ||
| US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
| US4642347A (en) * | 1985-05-21 | 1987-02-10 | American Home Products Corporation | 3(2-quinolinylalkoxy)phenols |
| US5245038A (en) * | 1987-11-06 | 1993-09-14 | Baxter Diagnostics Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
| IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
| DK0498722T3 (da) * | 1991-02-07 | 1998-03-09 | Roussel Uclaf | Nye bicycliske nitrogenforbindelser substitueret med en benzylgruppe, fremgangsmåde til deres fremstilling, de opnåede nye intermediærer, deres anvendelse som lægemidler og de pharmaceutiske præparater som de indgår i |
| US6004979A (en) * | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
| MX9200299A (es) * | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US6645969B1 (en) * | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5245036A (en) * | 1992-05-07 | 1993-09-14 | Dowelanco | Process for the preparation of 4-phenoxyquinoline compounds |
| US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
| GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| EP1195372A1 (en) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| US5840695A (en) * | 1994-10-07 | 1998-11-24 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
| DE19608653A1 (de) * | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| EP0912559B1 (en) * | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ES2286834T5 (es) * | 1996-08-12 | 2011-01-31 | Mitsubishi Tanabe Pharma Corporation | Medicamentos que comprenden un inhibidor de la rho quinasa. |
| AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US5885803A (en) * | 1997-06-19 | 1999-03-23 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
| ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| KR20010089171A (ko) * | 1998-08-21 | 2001-09-29 | 추후제출 | 퀴나졸린 유도체 |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| JP2002533544A (ja) * | 1998-12-23 | 2002-10-08 | バイエル アクチェンゲゼルシャフト | 黄色度が低いポリカーボネート |
| GB2345486A (en) * | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| BRPI0017548B8 (pt) * | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| HUP0400639A3 (en) * | 2000-12-21 | 2010-03-29 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them |
| MXPA03008658A (es) * | 2001-03-23 | 2005-04-11 | Bayer Ag | Inhibidores de rho-cinasa. |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| JP2005515176A (ja) * | 2001-11-03 | 2005-05-26 | アストラゼネカ アクチボラグ | 抗腫瘍剤としてのキナゾリン誘導体 |
| GB0128108D0 (en) * | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
| CA2472619A1 (en) * | 2002-01-10 | 2003-07-24 | Bayer Corporation | Fused pyrimidine derivates as rho-kinase inhibitors |
| US6943172B2 (en) * | 2002-01-23 | 2005-09-13 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
| CN1625555A (zh) * | 2002-02-01 | 2005-06-08 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
| WO2004081009A1 (en) * | 2003-03-12 | 2004-09-23 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as tgf-beta inhibitors |
| GB0318422D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| US7820683B2 (en) * | 2005-09-20 | 2010-10-26 | Astrazeneca Ab | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer |
-
2002
- 2002-03-22 MX MXPA03008658A patent/MXPA03008658A/es active IP Right Grant
- 2002-03-22 JP JP2002576234A patent/JP4329003B2/ja not_active Expired - Fee Related
- 2002-03-22 TW TW091105591A patent/TWI261055B/zh not_active IP Right Cessation
- 2002-03-22 PE PE2002000224A patent/PE20021011A1/es not_active Application Discontinuation
- 2002-03-22 AT AT02719303T patent/ATE325795T1/de active
- 2002-03-22 HN HN2002000067A patent/HN2002000067A/es unknown
- 2002-03-22 US US10/103,566 patent/US20030125344A1/en not_active Abandoned
- 2002-03-22 PT PT02719303T patent/PT1370553E/pt unknown
- 2002-03-22 UY UY27224A patent/UY27224A1/es unknown
- 2002-03-22 WO PCT/US2002/008659 patent/WO2002076976A2/en not_active Ceased
- 2002-03-22 EP EP02719303A patent/EP1370553B1/en not_active Expired - Lifetime
- 2002-03-22 MY MYPI20021020A patent/MY134783A/en unknown
- 2002-03-22 DK DK02719303T patent/DK1370553T3/da active
- 2002-03-22 CA CA2441492A patent/CA2441492C/en not_active Expired - Fee Related
- 2002-03-22 ES ES02719303T patent/ES2264477T3/es not_active Expired - Lifetime
- 2002-03-22 AR ARP020101069A patent/AR035791A1/es unknown
- 2002-03-22 DE DE60211317T patent/DE60211317T2/de not_active Expired - Lifetime
- 2002-03-22 AU AU2002250394A patent/AU2002250394A1/en not_active Abandoned
-
2006
- 2006-02-16 US US11/354,977 patent/US20060142313A1/en not_active Abandoned
- 2006-08-09 CY CY20061101118T patent/CY1107475T1/el unknown
-
2010
- 2010-02-02 US US12/698,386 patent/US20100137324A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR035791A1 (es) | 2004-07-14 |
| DE60211317T2 (de) | 2007-04-12 |
| EP1370553B1 (en) | 2006-05-10 |
| UY27224A1 (es) | 2002-10-31 |
| HN2002000067A (es) | 2003-10-24 |
| DE60211317D1 (de) | 2006-06-14 |
| MY134783A (en) | 2007-12-31 |
| EP1370553A2 (en) | 2003-12-17 |
| US20100137324A1 (en) | 2010-06-03 |
| CA2441492C (en) | 2011-08-09 |
| ES2264477T3 (es) | 2007-01-01 |
| WO2002076976A2 (en) | 2002-10-03 |
| JP2004524350A (ja) | 2004-08-12 |
| AU2002250394A1 (en) | 2002-10-08 |
| CY1107475T1 (el) | 2013-03-13 |
| TWI261055B (en) | 2006-09-01 |
| CA2441492A1 (en) | 2002-10-03 |
| PE20021011A1 (es) | 2003-02-01 |
| ATE325795T1 (de) | 2006-06-15 |
| WO2002076976A3 (en) | 2002-12-12 |
| US20030125344A1 (en) | 2003-07-03 |
| US20060142313A1 (en) | 2006-06-29 |
| JP4329003B2 (ja) | 2009-09-09 |
| HK1061030A1 (en) | 2004-09-03 |
| PT1370553E (pt) | 2006-09-29 |
| MXPA03008658A (es) | 2005-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1370553T3 (da) | Rho-kinase-inhibitorer | |
| DK1370552T3 (da) | Rho-kinase-inhibitorer | |
| ATE505471T1 (de) | Azaindol-kinaseinhibitoren | |
| DE60234125D1 (de) | E inhibitoren | |
| IS6968A (is) | Nýir týrósínkínasa tálmar | |
| NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
| CY2015028I2 (el) | Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης | |
| IS7599A (is) | Heterósýklískir kínasatálmar | |
| ATE286049T1 (de) | Pyridazinonaldose reductase inhibitoren | |
| NO20041293D0 (no) | Alkyn-aryl-fosfodiesterase-4-inhibitorer | |
| DE122008000002I1 (de) | Pyrrol substituierte indolin-2-on protein kinase inhibitoren | |
| EE05432B1 (et) | Prroloprimidiinid kui valgukinaasi inhibiitorid | |
| NO20021239L (no) | Pteridinoner som kinase-inhibitorer | |
| ATE452891T1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| NO20021820D0 (no) | Tyrosinkinaseinhibitorer | |
| PL373649A1 (en) | Kinase inhibitors | |
| DE60230934D1 (de) | Fab-i-inhibitoren | |
| SI1569907T1 (sl) | Na nikotinamidu osnovani kinazni inhibitorji | |
| EP1558609A4 (en) | KINASE INHIBITORS | |
| DK1272488T3 (da) | Tri-aryl-substitueret ethan-PDE4-inhibitorer | |
| BR0207810A (pt) | inibidores de deformilase de peptìdeo | |
| EP1569907A4 (en) | NICOTINAMIDE-BASED KINASE HEMMER | |
| DE60229669D1 (de) | X-2 inhibitoren | |
| NO20013535L (no) | Nöytrofil-funksjons-inhibitorer | |
| EP1651209A4 (en) | TYROSINE KINASE INHIBITORS |